Cargando…

Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries

INTRODUCTION: Standardized and validated criteria to define advanced Parkinson’s disease (PD) or identify patient eligibility for device-aided therapy are needed. This study assessed the psychometric properties of clinical indicators of advanced PD and eligibility for device-aided therapy in a large...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antonini, Angelo, Pahwa, Rajesh, Odin, Per, Henriksen, Tove, Soileau, Michael J., Rodriguez-Cruz, Ramon, Isaacson, Stuart H., Merola, Aristide, Lindvall, Susanna, Domingos, Josefa, Alobaidi, Ali, Jalundhwala, Yash J., Kandukuri, Prasanna L., Parra, Juan Carlos, Kukreja, Pavnit K., Onuk, Koray, Bergmann, Lars, Pike, James, Ray Chaudhuri, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857339/ https://www.ncbi.nlm.nih.gov/pubmed/35015215 http://dx.doi.org/10.1007/s40120-021-00313-9

Ejemplares similares

Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
por: Malaty, Irene A., et al.
Publicado: (2022)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Impact of advanced Parkinson’s disease on caregivers: an international real-world study
por: Martinez-Martin, Pablo, et al.
Publicado: (2023)

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
por: Antonini, Angelo, et al.
Publicado: (2022)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson’s Disease-Related Pill Burden Reduction in Advanced Parkinson’s Disease: A Retrospective Real-World Cohort Study
por: Soileau, Michael J., et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients
por: Fasano, Alfonso, et al.
Publicado: (2019)

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE‐PD observational study
por: Fasano, Alfonso, et al.
Publicado: (2022)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity
por: Dahodwala, Nabila, et al.
Publicado: (2020)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Odin, Per, et al.
Publicado: (2018)

Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States
por: Amjad, Fahd, et al.
Publicado: (2019)

Infusion Therapies in the Treatment of Parkinson’s Disease
por: van Laar, Teus, et al.
Publicado: (2023)

24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations
por: Thakkar, Sandeep, et al.
Publicado: (2021)

Close relationships in Parkinson´s disease patients with device‐aided therapy
por: Scharfenort, Monica, et al.
Publicado: (2021)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson’s Disease
por: Thaler, Avner, et al.
Publicado: (2022)

Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
por: Kovács, Norbert, et al.
Publicado: (2022)

An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients
por: Krüger, Rejko, et al.
Publicado: (2017)

DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2021)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies
por: Boyd, James T., et al.
Publicado: (2019)

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
por: Chaudhuri, K. Ray, et al.
Publicado: (2023)

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
por: Soileau, Michael J., et al.
Publicado: (2023)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
por: Pedersen, Stephen W, et al.
Publicado: (2017)

Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
por: Isaacson, Stuart H, et al.
Publicado: (2022)

The long‐term direct and indirect economic burden among Parkinson's disease caregivers in the United States
por: Martinez‐Martin, Pablo, et al.
Publicado: (2018)

Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury
por: Snedecor, Sonya J, et al.
Publicado: (2013)

Characterization of advanced Parkinson’s disease in Germany: results of the non-interventional OBSERVE-PD study
por: Pedrosa, David J., et al.
Publicado: (2022)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Abdominal compartment syndrome in trauma patients: New insights for predicting outcomes
por: Shaheen, Aisha W., et al.
Publicado: (2016)

Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
por: Henriksen, Tove, et al.
Publicado: (2021)

Evaluation of morning bradykinesia in Parkinson’s disease in a United States cohort using continuous objective monitoring
por: Isaacson, S.H., et al.
Publicado: (2022)

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?
por: Isaacson, Stuart H., et al.
Publicado: (2022)

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature
por: Isaacson, Stuart H., et al.
Publicado: (2022)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_520fhn7u2a2mh82fe7ruiej85i